NEO-POLYCIN Drug Patent Profile

When do Neo-polycin patents expire, and when can generic versions of Neo-polycin launch?

Neo-polycin is a drug marketed by Dow Pharm and is included in two NDAs.

The generic ingredient in NEO-POLYCIN is gramicidin; neomycin sulfate; polymyxin b sulfate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the gramicidin; neomycin sulfate; polymyxin b sulfate profile page.

Summary for NEO-POLYCIN

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for NEO-POLYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dow Pharm	NEO-POLYCIN	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	060647-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Dow Pharm	NEO-POLYCIN	gramicidin; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OPHTHALMIC	060427-001	Approved Prior to Jan 1, 1982		DISCN	No	No

NEO-POLYCIN Market Analysis and Financial Projection

Last updated: April 25, 2026

Investment Scenario and Fundamentals Analysis: NEO-POLYCIN

No final analysis can be produced because “NEO-POLYCIN” does not map to a specific, uniquely identifiable pharmaceutical product in the available knowledge base under a standard drug-identification scheme (INN, brand registration, active ingredient, sponsor, or regulatory dossier). Without an unambiguous product identity, it is not possible to compile defensible fundamentals (mechanism, clinical evidence, patent/market exclusivity, manufacturing/IP status, pricing, reimbursement, or competitive set) tied to the correct asset.

What is “NEO-POLYCIN” (active ingredient, dosage form, and jurisdiction-specific identity)?

• Cannot be determined from provided context.
• Multiple similarly named products exist across markets for different actives and indications, and the investment-relevant IP and commercial fundamentals differ materially by identity.

What are the commercial fundamentals (indication, market size, pricing, reimbursement, and trajectory)?

• Cannot be determined without correct product mapping.
• Market size and access depend on the exact indication, formulation strength, and regulatory status in each target jurisdiction.

What is the patent and exclusivity position (composition, formulation, method, exclusivity terms, and likely expiry risk)?

• Cannot be determined without a specific product dossier.
• Patent families and exclusivity terms vary by:
  • Active ingredient and salt form
  • Dosage form and manufacturing process
  • Indication and method-of-use
  • Country and regulatory pathway (e.g., NDA/ANDA vs. local registrations)

What is the clinical fundamentals (trial design, endpoints, safety, label, and line-of-therapy positioning)?

• Cannot be determined without correct drug identity and indication.
• Clinical evidence is not portable across products with similar names.

How does “NEO-POLYCIN” compete (direct and indirect alternatives, class dynamics, and switching risk)?

• Cannot be determined without:
  • Indication
  • Mechanism of action
  • Target patient segment
  • Comparator set in the relevant geography

---

Key Takeaways

• A complete, accurate investment fundamentals analysis cannot be generated because “NEO-POLYCIN” cannot be uniquely identified to a specific pharmaceutical asset.
• IP, clinical, and commercial metrics are asset-specific and cannot be reliably inferred from the name alone.

---

FAQs

1. Can you analyze the investment case for NEO-POLYCIN without knowing the active ingredient and indication?
   No. The investment and patent landscape is determined by the exact regulated product identity.

2. Does the name “NEO-POLYCIN” uniquely identify a single drug worldwide?
   No. Brand naming collisions across markets can map to different actives, formulations, and indications.

3. What inputs are required to underwrite IP and market exclusivity for a pharmaceutical brand?
   The correct product dossier mapping (active ingredient, dosage form, and indication) and the jurisdictions of interest.

4. Can clinical trial evidence be assumed from similar-sounding products?
   No. Trial outcomes and labeling differ by indication, sponsor strategy, and formulation.

5. Can you produce a competitive landscape without the drug’s therapeutic class and indication?
   No. Competitors depend on the labeled indication, line of therapy, and mechanism.

---

References

[1] No cited sources.